In 2015, Elizabeth Holmes and her firm, Theranos, seemed poised to revolutionize blood testing. Everything began to unravel in October of that year, however, when the Wall Street Journal published an investigative report questioning the accuracy of Theranos’s “Edison” blood-testing machine. Holmes was indicted in 2018. Her trial begins later this month. Sara Randazzo, a reporter with the Wall Street Journal, joins the show to discuss Holmes’s rise and fall, her upcoming trial, and what her case might mean for Silicon Valley start-up culture. You can follow Sara’s work, including her reporting on Holmes’s trial, here.